Samuel Goldlust, M.D.

Samuel Goldlust, M.D. is a neuro-oncologist at the Brain & Spine Tumor Institute at the John Theurer Cancer Center. Cancers and their treatments can cause neurologic symptoms, such as seizure, stroke, neuropathy, and cognitive effects, even without direct invasion of the nervous system. Dr. Goldlust specializes in the treatment of brain tumors and the neurological issues that arise from multi-modality cancer treatment and management.

Dr. Goldlust joined the John Theurer Cancer Center in July 2011 from Memorial Sloan-Kettering Cancer Center where he served as the Chief Fellow in the department of Neurology. Prior to this, Dr. Goldlust served as Chief Resident in the department of Neurology at New York University Hospitals.

Dr. Goldlust’s research focuses extensively on developing novel therapeutics for primary and metastatic brain tumors, improving care for tumor-related epilepsy, and developing strategies for neuro-protection in cancer patients. He is widely published in peer-reviewed journals, including Journal of Neuro-Oncology, Neurosurgery, and Annals of Oncology, and he is expanding the neuro-oncology clinical trial network at the Brain and Spine Tumor Institute to provide more treatment options that may help improve quality of life and survival.

Dr. Goldlust received his medical degree from The Ohio State University College of Medicine and is an active member of both the American Society of Clinical Oncology and the American Academy of Neurology. 
 Click here for a list of John Theurer Cancer Center Neurological Oncology clinical trials.